Statistical table
| Data structure | Type of test | p value | Statistical value and degrees of freedom (for parametric test) or sample size (for nonparametric test) | ||
|---|---|---|---|---|---|
| a | Distance travelled | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0005 (nondelayed early vs nondelayed late) and 0.13 (delayed early vs nondelayed late) | W(12) = 78 and 40 |
| Running speed | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0024 (nondelayed early vs nondelayed late) and 0.58 (delayed early vs nondelayed late) | W(12) = 72 and 15 | |
| Run period | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0005 (nondelayed early vs nondelayed late) and 0.42 (delayed early vs nondelayed late) | W(12) = 78 and 22 | |
| Target period | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0005 (delayed early vs delayed late) | W(12) = 78 | |
| Success rate | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0005 (delayed early vs delayed late) | W(12) = 78 | |
| b | Distance travelled (Fig. 4A2,B2,C2) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.24 (control vs no global), 0.10 (control vs no local), and 0.76 (control vs no cues) | W(11) = 28, −38, and 8 |
| Target period (Fig. 4A3,B3,C3) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.52 (control vs no global), 0.0049 (control vs no local), and 0.042 (control vs no cues) | W(11) = 16, 60, and 46 | |
| Success rate (Fig. 4A4,B4,C4) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.70 (control vs no global), 0.0068 (control vs no local), and 0.014 (control vs no cues) | W(11) = −9, 58, and 47 | |
| c | Distance travelled (Fig. 5B) | Normality assumed | Two-way ANOVA with Holm–Sidak post hoc multiple comparisons test | 0.87 (interaction), 0.75 (infusion type), and 0.50 (treatment period); 0.90 (pre vs CNQX), 0.90 (CNQX vs rec), 0.66 (pre vs veh), and 0.66 (veh vs rec) | Interaction, F(2,40) = 0.14; infusion type, F(1,20) = 0.11; treatment period, F(2,40) = 0.71 |
| Target period (Fig. 5C) | Normality assumed | Two-way ANOVA with Holm–Sidak post hoc multiple comparisons test | <0.0001 (interaction), 0.040 (infusion type), and <0.0001 (treatment period); <0.0001 (pre vs CNQX), <0.0001 (CNQX vs rec), 0.90 (pre vs veh), and 0.85 (veh vs rec) | Interaction, F(2,40) = 19.4; infusion type, F(1,20) = 4.81; treatment period, F(2,40) = 25.9 | |
| Success rate (Fig. 5D) | Normality assumed | Two-way ANOVA with Holm–Sidak post hoc multiple comparisons test | <0.0001 (interaction), 0.019 (infusion type), and <0.0001 (treatment period); <0.0001 (pre vs CNQX), <0.0001 (CNQX vs rec), 0.60 (pre vs veh), and 0.48 (veh vs rec) | Interaction, F(2,40) = 19.2; infusion type, F(1,20) = 6.55; treatment period, F(2,40) = 32.2 | |
| d | Target period, 1st group (Fig. 7A) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.031 (target 1, pre 1 vs shift 1), 0.031 (target 1, pre 2 vs shift 5), 0.031 (target 2, pre 1 vs shift 1), 0.031 (target 2, pre 2 vs shift 5), 0.031 (target 3, pre 2 vs shift 5), and 0.031 (target 3, shift 5 vs shift 6) | W(6) = −21, 21, 21,−21, 21, and 21 |
| Target period, 2nd group (Fig. 7B) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.031 (target 1, pre1 vs shift 1), 0.031 (target 1, pre 2 vs shift 5), 0.031 (target 1, shift 5 vs shift 6), 0.031 (target 2, pre 2 vs shift 5), 0.031 (target 3, pre 1 vs shift 1), and 0.031 (target 3, pre 2 vs shift 5) | W(6) = −21, 21, −21, 21, 21, and −21 | |
| e | Success rate (Fig. 7D) | Normality not assumed | Wilcoxon matched-pairs signed rank test | 0.0049 (distal vs proximal) | W(12) = 60 |
| f | Distance travelled (Fig. 8C) | Normality assumed | Two-way ANOVA with Holm–Sidak post hoc multiple comparisons test | 0.94 (interaction), 0.36 (genotype) and 0.024 (task stage); 0.81 (nondelayed early KO vs nondelayed early WT), 0.81 (nondelayed late KO vs nondelayed late WT), 0.81 (delayed early KO vs delayed early WT), and 0.81 (delayed late KO vs delayed late WT) | Interaction, F(3,33) = 0.13; genotype, F(1,11) = 0.92; task stage, F(3,33) = 3.58 |
| Target period (Fig. 8D) | Normality assumed | Two-way ANOVA with Holm–Sidak post hoc multiple comparisons test | 0.0026 (interaction), 0.23 (genotype), and 0.0003 (task stage); 0.91 (nondelayed early KO vs nondelayed early WT), 0.25 (nondelayed late KO vs nondelayed late WT), 0.25 (delayed early KO vs delayed early WT), and 0.011 (delayed late KO vs delayed late WT) | Interaction, F(3,33) = 5.84; genotype, F(1,11) = 1.63; task stage, F(3,33) = 8.35 | |
| g | Target 3 period (Fig. 8H) | Normality not assumed | Mann-Whitney U test | p = 0.0023 (KO vs WT) | U(6,7) = 1 |
| Relearning index (Fig. 8I) | Normality not assumed | Mann-Whitney U test | p = 0.022 (KO vs WT) | U(6,7) = 5 |